Status:
UNKNOWN
The Study of Chinese Medicine for the Treatment of Primary Osteoporosis
Lead Sponsor:
Wangjing Hospital, China Academy of Chinese Medical Sciences
Conditions:
Primary Osteoporosis
Eligibility:
All Genders
45-80 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the efficacy and possible mechanism of traditional Chinese medicine in the treatment of primary osteoporosis (Kidney Yang Deficiency Syndrome).It is a randomiz...
Detailed Description
The subjects are selected according to the inclusion criteria and exclusion criteria. Using the network random system, 120 subjects who meet the research criteria are randomly divided into control gro...
Eligibility Criteria
Inclusion
- It meets the diagnostic criteria of Western medicine for primary osteoporosis. the diagnostic criteria of osteoporosis based on the bone mineral density of central axis (lumbar spine 1-4, femoral neck or total hip) or 1/3 bone mineral density of distal radius measured by DXA is t-value ≤ - 2.5;
- It meets the syndrome differentiation standard of primary osteoporosis with Kidney Yang Deficiency Syndrome;
- Female menopause \> 2 years and 45 years ≤ age \< 80 years, or 50 years ≤ male \< 80 years;
- Visual Analogue Score (VAS) was used to evaluate pain ≥ 4 points;
- Voluntarily participate in this clinical study and sign the informed consent form.
Exclusion
- Osteoporotic fracture has occurred, or t-value \> - 2.5;
- Female premenopausal or menopausal years ≤ 2 years, female age \< 45 years or ≥ 80 years, male age \< 50 years or ≥ 80 years;
- VAS pain score \< 4;
- Lumbar fusion or severe degenerative changes hinder the measurement of normal bone mineral density, and there are less than 2 consecutive intact lumbar vertebrae for DXA measurement and evaluation;
- Patients with malignant tumor, cardiovascular, cerebrovascular, liver disease, kidney disease, hematopoietic system and other serious primary diseases;
- secondary osteoporosis: diabetes, thyroid disease, Cushing syndrome and other metabolic diseases, rheumatoid arthritis, multiple myeloma, gout, absorption syndrome, systemic lupus erythematosus and other systemic diseases.
- Use drugs affecting bone metabolism, such as bisphosphonates, glucocorticoids, calcitonin, anticonvulsant drugs, heparin and other drugs within 3 months before signing the informed consent;
- History of serious mental illness or poor compliance;
- Allergic constitution, allergy to known components of the drug, allergy to calcium or vitamin D;
- Those who participated in other clinical trials within 3 months.
- Rejection Criteria:
- False diagnosis and false inclusion;
- Not receiving one treatment;
- During the study, in addition to the study medication, drugs known or likely to affect bone metabolism were used.
- Shedding Standard:
- The subjects withdrew from the test by themselves;
- Loss of follow-up;
- The subject received treatment at least once, and there were serious complications or complications and serious adverse events;
- Although the test was completed, the dosage of the subject was not within the range of 80%-120% of the dosage that should be taken.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05370898
Start Date
July 1 2022
End Date
May 1 2023
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wangjing Hospital of China Academy of Chinese Medical Sciences
Beijing, China